News
After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Most employers are well aware of the devastating effects the pandemic has had on employee retention. Read on to find out how long you can expect your staff to stay and how to keep them.
Bayer has lured another top oncology expert from GlaxoSmithKline. Tara Frenkl is joining the Germany-based life sciences giant as the new head of oncology development.
Long COVID is loosely defined as COVID-19 symptoms that persist for longer than four weeks from an initial diagnosis. Here’s a look at the latest in long COVID research.
The WHO has indicated support for Pfizer’s Paxlovid and reversing a previous decision on using antiviral remdesivir, now recommending it in cases of mild to moderate COVID-19.
New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and psychological indications.
Toxicities and concerning patient survival data sparked a U.S. Food and Drug Administration advisory committee to recommend shutting the door on single-arm clinical studies of PI3K inhibitors.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
The COVID-19 pandemic will end one day and, when it does, some biopharma companies will need to revert to a more normal way of working with others.
Servier is poised to go to market soon after the Phase III trial of its proposed drug for leukemia closed with positive results.
Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.